The World's First Universal Oral Snakebite Antidote

Our broad-spectrum oral therapy, designed for rapid, accessible snakebite treatment, enabling earlier intervention and improving outcomes worldwide

Explore Our Science Request Briefing

The Problem

Snakebite Envenoming,
a WHO-classified neglected tropical disease

Snakebite Envenoming remains one of the world's most overlooked yet devastating medical emergencies. Each year, millions of people are affected, with outcomes heavily dependent on how quickly treatment can be delivered.

It kills more people each year than rabies, dengue and yellow fever combined. The standard of care has not fundamentally changed since the 1890s.

Every year, the world faces:

0MSnakebites
0MSerious envenomings
0KDeaths
0KLife-changing disabilities

One death every four minutes...

Nouniversaltreatmentexists.Untilnow.

Our Unique Solution: The First Breakthrough in 100+ Years

Broad-spectrum coverage

Species specific

Oral, heat-stable and field-ready

IV, cold-chain, hospital-only

Prevents permanent disabilities

Local tissue damage

Cost-effective

Socioeconomic burden

Serpentium — Broad Spectrum Antivenom Combination Therapy

Explore the science

Loading globe

Pipeline

Discovery

Preclinical

ClinicalNOW

Approval

Deployment

Global Reach

Discovery

01Complete

Rooted in 20+ years of research

Two decades of venom pharmacology and biochemistry research at the University of Reading. Patented combination therapy of repurposed drugs with confirmed freedom to operate

✓IP protected
✓Built on long-term research into venom pharmacology

TimingFoundation phase complete

Preclinical

02Complete

Tested against the world's most medically significant snakes

Validated across 70+ venoms globally including vipers, cobras and asps. Provided delay to death in 100% of snakes tested, with protection against 95% of bites in only one dose

✓Tested across diverse venom types
✓Designed for real-world bites, where the snake is often unknown

TimingPreclinical validation complete

Clinical

03Current

Moving into first-in-human trials

Clinical trial plan (CT04) published. Phase I safety studies in healthy volunteers in preparation, followed by Phase II in snakebite patients in high-burden geography

✓Trial design approved by Indian regulatory authority (CDSCO)
✓Phase I + II trials as per emergency authorisation protocol in India

TimingPhase I ~Q2 2026, Phase II ~Q3 2026

Approval

04Upcoming

A regulatory path designed for field realities

A multi-region regulatory plan designed to support early access in high-burden countries, scalable procurement across global health markets, and structured approval in developed healthcare systems

✓Prioritising regions with urgent unmet need
✓Supporting broad distribution through global health channels

TimingFirst approvals targeted October 2026

Deployment

05Upcoming

Built to reach where antivenom cannot

Heat-stable oral format means treatment can be stocked in clinics, pharmacies and field kits, not just hospitals with cold chain

✓High burden market entry: India-first launch
✓Scalable distribution through pharma partner

TimingFirst launch targeted late 2026

Global Reach

06Upcoming

A path to 125+ countries

Tiered rollout from India into South Asian markets e.g., Bangladesh, Pakistan and Sri Lanka, then Latin America, Africa, Southeast Asia and developed markets